Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 10 clinical trials
MIBG With Dinutuximab +/- Vorinostat

2 pediatric dose. An expansion cohort of an additional 6 patients will then be enrolled. If tolerable, vorinostat will then be added to the third dose level. A 6 patient expansion cohort may then be

ganglioneuroblastoma
catecholamines
dinutuximab
iobenguane
tumor cells
  • 38 views
  • 25 May, 2022
  • 11 locations
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation

The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT

cancer
transplant conditioning
graft versus host disease
cell transplantation
azacitidine
  • 2 views
  • 04 Oct, 2022
  • 1 location
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer

The purpose of this study is to test the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer

epidermal growth factor
measurable disease
erbb2
growth factor
EGFR
  • 3 views
  • 04 Oct, 2022
  • 1 location
Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

This phase II trial studies how well pembrolizumab and tamoxifen with or without vorinostat work for the treatment of estrogen receptor positive breast cancer. Immunotherapy with monoclonal

  • 0 views
  • 22 Mar, 2022
  • 1 location
Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and

remission
bone marrow procedure
leukemia
cyclophosphamide
follicular lymphoma
  • 24 views
  • 07 Feb, 2022
  • 1 location
An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn's Disease and Maintenance Therapy With Ustekinumab

loss and malnutrition. CD has no cure, but symptoms can sometimes be controlled with medicine. Researchers want to see if it is safe to treat CD with the medicine vorinostat. It is thought that

maintenance treatment
enteropathy
malnutrition
corticosteroids
natalizumab
  • 53 views
  • 22 Oct, 2022
  • 1 location
A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL) (OPTIMUM)

The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma

etoposide
total bilirubin
melphalan
neutrophil count
bone marrow procedure
  • 58 views
  • 25 Oct, 2022
  • 20 locations
Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas

treatment and are undergoing stem cell transplant. Drugs used in chemotherapy, such as olaparib, vorinostat, gemcitabine, busulfan, and melphalan, work in different ways to stop the growth of cancer cells

melphalan
hysterectomy
salvage therapy
lymphoma
large b-cell lymphoma
  • 2 views
  • 16 Oct, 2022
  • 1 location
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma

This research is being done to study the safety of implanting and retrieving a microdevice that releases up to 19 drugs directly within a cancerous lesion as a possible tool to evaluate the effectiveness of several approved cancer drugs against cutaneous T cell lymphoma and peripheral T cell lymphoma

romidepsin
corticosteroids
neutrophil count
peripheral t-cell lymphoma
lymphoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics (CHARGE)

This is an open-label, multi-center, phase I study designed to assess the maximum tolerated dose of ribociclib and belinostat in combination. The trial will open with a dose escalation followed by an expansion cohort at the identified dose. Dose escalation will be open to the enrollment of patients diagnosed with …

liver metastasis
breast cancer
measurable disease
erbb2
metastasis
  • 0 views
  • 11 May, 2022
  • 2 locations